DAVY VIEW

Amryt has reached an agreement to acquire Aegerion Pharmaceuticals (subsidiary of Novelion) in an all-paper transaction. The deal will provide Amryt with an expanded commercial footprint and global infrastructure in the rare disease space with two approved products (Lomitapide and Metreleptin) in the US and EMEA – the combined group had 2018 pro-forma revenues of $136.5m (Amryt FY 18: €14.5m). The transaction will also provide Amryt with the financial flexibility to fund further pipeline development – the company intends to raise $60m at a 20% discount to the implied equity transaction value (combined $310.7m). Our forecasts are under review.